Drug Search Results
More Filters [+]

Onercept

Alternative Names: onercept
Latest Update: 2021-02-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TNF Inhibitor

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Onercept

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Erythema|Arthritis, Psoriatic|Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Not Applicable

P3

Completed

Psoriasis|Erythema

2006-03-23

2004-000530-37

P3

Completed

Erythema|Psoriasis

2006-03-01

NCT00090129

P3

Terminated

Arthritis, Psoriatic|Psoriasis

2005-06-01

Recent News Events